Selected Portfolio

Denotes acquired investment

Denotes public company

CIRCLE PHARMA

Circle Pharma operates an indication-agnostic discovery engine for the development of cell permeable macrocyclic peptide therapeutics. Circle's discovery engine combines computational structure-based design with automated, fully synthetic chemistry.
VISIT SITE

EIKON THERAPEUTICS

Eikon Therapeutics is a new biopharmaceutical company employing the revolutionary technology of single molecule imaging at the interface of chemistry, engineering and biology to discover novel treatments for life-threatening.
VISIT SITE

HEXAGON BIO

Hexagon's interdisciplinary platform discovers evolutionarily refined small molecules and their protein targets directly from fungal genomes. Hexagon then develops these molecules into therapeutics to combat human disease.
VISIT SITE

A2 BIOTHERAPEUTICS

A2 Biotherapeutics is an early-stage biotechnology company located in Southern California that develops novel medicines for serious illnesses. A2 utilizes an advanced targeting technology platform to increase the effectiveness of the body’s natural immune defenses.
VISIT SITE

ACCENT THERAPEUTICS

Accent Therapeutics is developing small molecule, precision cancer therapies in the emerging field of epitranscriptomics. By targeting cancer-linked RNA-modifying proteins (RMPs) with precision drugs, Accent is translating extraordinary, novel science into life-changing therapies for patients.
VISIT SITE

ESCIENT PHARMACEUTICALS

Escient Pharmaceuticals is advancing first-in-class G Protein-Coupled Receptor (GPCR)-targeted drugs to address serious, unserved medical needs across a broad range of therapeutic indications. Escient will initially pursue medicines for neuro-immuno-inflammatory and autoreactive diseases.
VISIT SITE

PLEXIUM

Plexium is focused on the identification of E3 ligase modulating small molecules to treat cancer and neurodegenerative diseases. Plexium’s platform allows screening for molecular-glue degraders to be conducted via massively high throughput cell-based assays utilizing DNA-encoded libraries.
VISIT SITE

NURA BIO

Nura Bio (formerly Proneurotech) seeks to alter the course of neurological diseases by targeting fundamental pathways underlying axon degeneration and neuroimmune regulation to preserve neuronal integrity.
VISIT SITE

REVOLUTION MEDICINES

Revolution Medicines is an innovative and dynamic organization of expert cellular, structural and computational biologists, medicinal and synthetic chemists, pharmacologists, engineers and business executives working together to discover and develop new medicines for cancer patients.
VISIT SITE

SURROZEN

Surrozen is discovering and developing novel regenerative medicines with a focus on unlocking the powerful self-renewal properties of the body through specific control of the Wnt signaling pathway, which plays a critical role in stem cell maintenance, tissue regeneration and other important developmental processes.
VISIT SITE

SYNTHEKINE

Synthekine is focused on discovery and developing best in class cytokine therapeutics. The company is generating an array of “synthetic” cytokines and will deploy these unique molecules to tune the immune system in new and interesting ways for the potential treatment of a range of diseases, from cancer to autoimmune disorders.
VISIT SITE

TENAYA THERAPEUTICS

Tenaya is focused on creating therapeutics for heart failure patients. Tenaya seeks to address heart disease through three distinct and multi-modality platforms: a Regeneration Platform, a Gene Therapy Platform, and a Precision Medicine Platform.
VISIT SITE

ARCUS BIOSCIENCES

Arcus Biosciences is an oncology company researching adaptive immunity and innate immunity to discover drugs with broad applicability in combination therapies.
VISIT SITE

RIBON THERAPEUTICS

Ribon Therapeutics is a biotech company focused on developing first-in-class therapeutics targeting monoADP-ribosylating PARPs for cancer.
VISIT SITE

KALLYOPE

Kallyope is dedicated to unlocking the therapeutic potential of the gut-brain axis. Kallyope integrates advanced technologies in sequencing, bioinformatics, neural imaging, cellular and molecular biology, and human genetics to provide an understanding of gut-brain biology that leads to transformational therapeutics to improve human health.
VISIT SITE

GRITSTONE ONCOLOGY

Gritstone Oncology is committed to progressing the field of immunotherapy, with a goal to eradicate cancer by initially developing personalized immunotherapies that focus on the unique and individual nature of a patient’s tumor.
VISIT SITE

RAPT THERAPEUTICS

RAPT Therapeutics (formerly FLX Bio) aims to conquer cancer and inflammatory disease in our lifetime. RAPT is fully focused on developing oral therapeutics that intelligently target key drivers of the immune system to transform the treatment of cancer and inflammation, and improve and empower countless lives.
VISIT SITE

NEURONA THERAPEUTICS

Neurona is a cell therapy company focused on the discovery and development of disease-altering treatments for intractable neuropsychiatric disorders. The company seeks to become an industry leader in the neural stem cell field with multiple therapeutic product candidates.
VISIT SITE

ORIC PHARMACEUTICALS

ORIC is a small molecule oncology company focused on combating the growing resistance problem to current molecularly targeted drugs.
VISIT SITE

EFFECTOR THERAPEUTICS

eFFECTOR is pioneering a new class of small molecule drugs that act by selectively regulating translation, also known as protein synthesis. The company unites breakthrough insights into the mechanisms of translational control with a proven approach to product invention.
VISIT SITE

CARMOT THERAPEUTICS

Carmot is a clinical-stage company dedicated to the discovery and development of innovative medicines. Using Chemotype Evolution, a transformative, patented drug discovery approach, Carmot has developed a portfolio of drug candidates in metabolic disease and oncology.
VISIT SITE

CONSTELLATION PHARMACEUTICALS

Constellation is a pioneer in the discovery and development of novel therapeutics that target the writer, reader and eraser classes of epigenetic regulators and modulate gene expression in a more selective manner. The Company is developing novel therapeutics that address serious unmet medical needs in cancer patients.
VISIT SITE

NGM BIO

NGM Bio is a research-driven, clinical stage biopharmaceutical company with a drug discovery platform that has generated a pipeline of first-in-class biologic development candidates.
VISIT SITE

NURIX

Nurix is focused on discovering and developing therapies that modulate the ubiquitin proteasome system (UPS) for the treatment of a broad range of human disorders, most notably cancer.
VISIT SITE

ARAGON PHARMACEUTICALS

Aragon is creating a new class of nuclear receptor targeting drugs that overcome the biology of hormone resistant cancers. Aragon was acquired by Johnson & Johnson in August 2013 for up to $1B.
VISIT SITE

EXONICS THERAPEUTICS

Exonics discovers and develops medicines for the treatment of neuromuscular diseases. The Company develops gene editing technologies like CRISPR/Cas9 to permanently correct the majority of Duchenne muscular dystrophy mutations. Exonics was acquired by Vertex on June 6, 2019 for up to $1B.
VISIT SITE

FLEXUS BIOSCIENCES

Flexus was founded with the mission to create new cancer therapeutics through the innovative application of unexploited insights in immunology. Flexus Biosciences was acquired by Bristol-Myers Squibb in April 2015 for $1.3B.
VISIT SITE

IMMUNE DESIGN

Immune Design is an immunotherapy oncology company focused on engineering technologies to activate the immune system’s natural ability to fight disease. Immune Design was acquired by Merck in February 2019 for $0.3B.
VISIT SITE

PELOTON THERAPEUTICS

Peloton Therapeutics is advancing a first-in-class discovery and development pipeline in oncology, comprising several well-differentiated small-molecule programs. Peloton was acquired by Merck in May 2019 for up to $2.35B.
VISIT SITE

SERAGON PHARMACEUTICALS

Seragon is focused on developing new treatments for estrogen-driven cancers based on its Selective Estrogen Receptor Degrader (SERD) platform. Seragon was acquired by Genentech, a member of the Roche Group, in August 2014 for $0.8B.
VISIT SITE

(Does not include inactive companies with minimal return to the Portfolio. The portfolio companies presented on this site are being provided for discussion and illustrative purposes only. Any portfolio company or investment cited on this page may or may not be in the portfolio of a current fund managed by The Column Group. They should not be considered a recommendation to investment in any financial instrument and they do not depict the risks associated with each investment. Further, past performance is no guarantee of future results.)

Scroll to Top